FREDRIK WERMERLING TEAM

Autoimmune and inflammatory diseases – novel treatment strategies

 

About

Using experimental systems and patient material we study the immune system with a specific interest related to inflammation, autoimmune disease and cancer immunotherapy.

A major part of the different projects in the lab relates to antibodies, neutrophils and T cells. We also spend a lot of effort into using CRISPR/Cas9 based custom screens as a discovery platform to understand complex biological processes and to identify novel drug targets. To facilitate the design of these screens, we have developed a software that we call Green Listed. A blog post describing our approach can be found at Addgene.

Currently several projects in the lab relates to our interest in signaling downstream of the IL-4 receptor (IL-4R). The basis for this interest was the unexpected finding that the expression of the IL-4R is essential for the activity of a drug (IVIG) used to treat patients with autoimmune disease, and that the expression of this receptor is highly regulated during inflammation (Anthony et al, 2011, Nature and Wermeling et al, 2013, PNAS).

 

Selected publications

Link to publications on PubMed here.

 

Panda SK, Boddul SV, Jiménez-Andrade GY, Jiang L, Kasza Z, Fernandez-Ricaud L, Wermeling F. Green listed-a CRISPR screen tool. Bioinformatics. 2017 Apr 1;33(7):1099-1100.

 

Wermeling F, Anthony RM, Brombacher F, Ravetch JV. Acute inflammation primes myeloid effector cells for anti-inflammatory STAT6 signaling. Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13487-91. PDF

Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011 Jun 19;475(7354):110-3.

 

Wermeling F, Lind SM, Jordö ED, Cardell SL, Karlsson MC. Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. J Exp Med. 2010 May 10;207(5):943-52. PDF

Wermeling F, Chen Y, Pikkarainen T, Scheynius A, Winqvist O, Izui S, Ravetch JV, Tryggvason K, Karlsson MC. Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus. J Exp Med. 2007 Oct 1;204(10):2259-65. PDF